The relationship between a UCSB researcher and several victims of polycystic kidney disease has led to the development of a new designer drug that can travel through the bloodstream to the kidneys of laboratory animals
Scientists at UC Santa Barbara have demonstrated in the laboratory that a new drug is effective in treating a very common kidney disease –– although it will be a few years before it becomes available for clinical testing. The findings resulted from a collaboration between UCSB and a biotech firm based in Indiana. The study is published in this week's Journal of the American Society of Nephrology.
Thomas Weimbs, an Associate Professor in the Molecular, Cellular and Developmental Biology Department since 2007, has a lab at UCSB focuses on uncovering the underlying mechanisms of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a common genetic disease for which a cure still remains elusive. He is a leading expert in biomedical research.
